Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3881-3890 Newer>

The Motley Fool July 20, 2007 Jack Uldrich	Nucryst's Nanocrystal Coup Nanosys receives FDA clearance on its anti-microbial cream and shares soar.
The Motley Fool July 20, 2007 Brian Orelli	Arena Keeps Burning the Cash The pipeline drugs being developed by Arena Pharmaceuticals hold promise, but it will be a while before, or if, the company shows a profit.
The Motley Fool July 20, 2007 Brian Lawler	Glaxo Heats Up the Vaccine Battle GlaxoSmithKline's cervical cancer vaccine gets a positive recommendation in the EU. Sales could begin in early 2008 and will compete with Gardasil, by rival Merck.
The Motley Fool July 20, 2007 Brian Orelli	Baxter's Mixed Message A recall of Baxter BioScience's COLLEAGUE infusion pumps seems to have over-shadowed healthy quarterly earnings reports.
The Motley Fool July 20, 2007 Andrew R. Vaino	BioCryst Is for the Birds Fears of bird flu resurrected a drug for this small pharma, and it has some other promising compounds in the pipeline. Based only on its pipeline size, BioCryst should be valued higher. But make no mistake: This is a risky stock.
The Motley Fool July 20, 2007 Billy Fisher	Wyeth Keeps Working Its Magic The drugmaker's second-quarter boasts 12% earnings growth. Of particular promise was the reversal over first-quarter for its top seller, the antidepressant Effexor.
The Motley Fool July 19, 2007 Brian Orelli	Head to the U.S. to Sue Your Neighbor Danish Novo Nordisk and French Sanofi-Aventis fight over insulin-delivery systems. Since the patent covers the U.S., the two companies will need to fight it out in U.S. courts.
The Motley Fool July 19, 2007 Brian Orelli	Trimeris Reaches a Plateau Drug developer Trimeris needs to push another drug out of its pipeline because sales of its only drug, Fuzeon, appear to be hitting the wall. Investors, take note.
The Motley Fool July 19, 2007 Brian Lawler	Will Encysive's FDA Challenge Fail? The pharmaceutical gets set for a showdown with the FDA. Investors should think long and hard about whether shares of Encysive are worth holding, considering that the likely result of this dispute resolution process won't be positive.
The Motley Fool July 18, 2007 Brian Orelli	Metabasis Gets Whacked At some point in the future, Metabasis will likely need to sell more shares or find another partner willing to provide a cash infusion.
<Older 3881-3890 Newer> Return to current articles.